0001371128 false Q2 --12-31 0001371128
2022-01-01 2022-06-30 0001371128 2022-08-09 0001371128 2022-06-30
0001371128 2021-12-31 0001371128 2022-04-01 2022-06-30 0001371128
2021-04-01 2021-06-30 0001371128 2021-01-01 2021-06-30 0001371128
us-gaap:PreferredStockMember 2020-12-31 0001371128
NEWH:MezzanineMember 2020-12-31 0001371128
us-gaap:CommonStockMember 2020-12-31 0001371128
us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001371128
us-gaap:RetainedEarningsMember 2020-12-31 0001371128 2020-12-31
0001371128 us-gaap:PreferredStockMember 2021-12-31 0001371128
NEWH:MezzanineMember 2021-12-31 0001371128
us-gaap:CommonStockMember 2021-12-31 0001371128
us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001371128
us-gaap:RetainedEarningsMember 2021-12-31 0001371128
us-gaap:PreferredStockMember 2021-01-01 2021-06-30 0001371128
NEWH:MezzanineMember 2021-01-01 2021-06-30 0001371128
us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001371128
us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30
0001371128 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30
0001371128 us-gaap:PreferredStockMember 2022-01-01 2022-06-30
0001371128 NEWH:MezzanineMember 2022-01-01 2022-06-30 0001371128
us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001371128
us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30
0001371128 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30
0001371128 us-gaap:PreferredStockMember 2021-06-30 0001371128
NEWH:MezzanineMember 2021-06-30 0001371128
us-gaap:CommonStockMember 2021-06-30 0001371128
us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001371128
us-gaap:RetainedEarningsMember 2021-06-30 0001371128 2021-06-30
0001371128 us-gaap:PreferredStockMember 2022-06-30 0001371128
NEWH:MezzanineMember 2022-06-30 0001371128
us-gaap:CommonStockMember 2022-06-30 0001371128
us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001371128
us-gaap:RetainedEarningsMember 2022-06-30 0001371128 2021-01-01
2021-12-31 0001371128 NEWH:EmployeeMember 2015-03-23 2015-03-24
0001371128 srt:DirectorMember 2015-08-30 2015-09-02 0001371128
2022-03-24 0001371128 srt:DirectorMember 2015-09-02 0001371128
NEWH:EmployeeMember 2021-02-18 2021-02-18 0001371128
NEWH:EmployeeMember 2021-02-18 0001371128 2021-09-29 0001371128
NEWH:EmployeeMember
us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-02-18
2021-02-18 0001371128 NEWH:EmployeeMember
us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-02-18
0001371128 NEWH:EmployeeMember
NEWH:FirstInstallmentTwentyFourMonthsMember 2021-02-18 2021-02-18
0001371128 NEWH:EmployeeMember
NEWH:FirstInstallmentTwentyFourMonthsMember 2021-03-18 2021-03-18
0001371128 NEWH:EmployeeMember
us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-03-18
0001371128 NEWH:EmployeeMember
NEWH:FirstInstallmentThirtySixMonthsMember 2021-03-18 2021-03-18
0001371128 NEWH:EmployeeMember
us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-04-12
0001371128 NEWH:EmployeeMember
NEWH:FirstInstallmentTwentyFourMonthsMember 2022-04-11 2022-04-12
0001371128 2022-03-01 0001371128 2022-02-28 2022-03-01 0001371128
NEWH:EmployeeMember NEWH:FirstInstallmentThirtySixMonthsMember
2022-03-15 0001371128 NEWH:EmployeeMember
NEWH:FirstInstallmentThirtySixMonthsMember 2022-03-14 2022-03-15
0001371128 NEWH:EmployeeMember 2022-04-11 2022-04-12 0001371128
NEWH:EmployeeMember 2022-04-12 0001371128 NEWH:EmployeeMember
NEWH:FirstInstallmentTenMonthsMember 2022-04-11 2022-04-12
0001371128 NEWH:EmployeeMember NEWH:FirstInstallmentTenMonthsMember
2022-04-12 0001371128 NEWH:EmployeeMember
NEWH:FirstInstallmentTwentyTwoMonthsMember 2022-04-11 2022-04-12
0001371128 2022-01-01 2022-03-31 0001371128
us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001371128
us-gaap:ComputerEquipmentMember 2022-01-01 2022-06-30 0001371128
us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-06-30
0001371128 us-gaap:SeriesCPreferredStockMember 2022-01-01
2022-06-30 0001371128 us-gaap:SeriesCPreferredStockMember
2022-06-30 0001371128 us-gaap:SeriesBPreferredStockMember
2021-01-13 2021-01-14 0001371128
us-gaap:SeriesCPreferredStockMember 2021-03-25 2021-03-26
0001371128 2021-03-25 2021-03-26 0001371128
us-gaap:SeriesCPreferredStockMember 2021-03-26 0001371128
us-gaap:SeriesCPreferredStockMember
us-gaap:MeasurementInputPriceVolatilityMember 2021-03-26 0001371128
us-gaap:SeriesCPreferredStockMember
us-gaap:MeasurementInputExpectedTermMember 2021-03-26 0001371128
us-gaap:ConvertibleDebtMember 2021-01-01 2021-06-30 0001371128
us-gaap:InvestorMember NEWH:SecuritiesPurchaseAgreementMember
2021-01-01 2021-06-30 0001371128 srt:MaximumMember
us-gaap:InvestorMember us-gaap:CommonStockMember
NEWH:SecuritiesPurchaseAgreementMember 2021-01-01 2021-06-30
0001371128 srt:MaximumMember us-gaap:InvestorMember
us-gaap:WarrantMember NEWH:SecuritiesPurchaseAgreementMember
2021-06-30 0001371128 us-gaap:InvestorMember
us-gaap:CommonStockMember NEWH:SecuritiesPurchaseAgreementMember
2021-06-30 0001371128 us-gaap:InvestorMember
NEWH:SecuritiesPurchaseAgreementOneMember 2021-01-01 2021-06-30
0001371128 srt:MaximumMember us-gaap:InvestorMember
us-gaap:CommonStockMember NEWH:SecuritiesPurchaseAgreementOneMember
2021-01-01 2021-06-30 0001371128 srt:MaximumMember
us-gaap:InvestorMember us-gaap:WarrantMember
NEWH:SecuritiesPurchaseAgreementOneMember 2021-01-01 2021-06-30
0001371128 us-gaap:InvestorMember
NEWH:SecuritiesPurchaseAgreementOneMember 2021-06-30 0001371128
NEWH:ConvertiblePromissoryNotesMember 2021-01-01 2021-06-30
0001371128 srt:MinimumMember NEWH:ConvertiblePromissoryNotesMember
2021-06-30 0001371128 srt:MaximumMember
NEWH:ConvertiblePromissoryNotesMember 2021-06-30 0001371128
NEWH:ConvertiblePromissoryNotesTwoMember 2021-01-01 2021-06-30
0001371128 NEWH:ConvertiblePromissoryNotesTwoMember 2021-06-30
0001371128 srt:MinimumMember
NEWH:ConvertiblePromissoryNotesTwoMember 2021-06-30 0001371128
srt:MaximumMember NEWH:ConvertiblePromissoryNotesTwoMember
2021-06-30 0001371128 2021-03-26 0001371128 us-gaap:OptionMember
2022-01-01 2022-06-30 0001371128 NEWH:ExercisablePricesOneMember
2022-06-30 0001371128 NEWH:ExercisablePricesOneMember 2022-01-01
2022-06-30 0001371128 NEWH:ExercisablePricesTwoMember 2022-06-30
0001371128 NEWH:ExercisablePricesTwoMember 2022-01-01 2022-06-30
0001371128 NEWH:ExercisablePricesThreeMember 2022-06-30 0001371128
NEWH:ExercisablePricesThreeMember 2022-01-01 2022-06-30 0001371128
NEWH:WarrantOneMember 2022-06-30 0001371128 NEWH:WarrantTwoMember
2022-06-30 0001371128 NEWH:WarrantThreeMember 2022-06-30 0001371128
NEWH:WarrantFourMember 2022-06-30 0001371128 NEWH:WarrantFiveMember
2022-06-30 0001371128 2022-03-14 2022-03-15 0001371128 2022-03-15
iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-Q
(Mark
One)
☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR
THE QUARTERLY PERIOD ENDED
JUNE 30,
2022
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR
THE TRANSITION PERIOD FROM __________ TO __________
COMMISSION
FILE NUMBER:
000-54819
NEWHYDROGEN, INC.
(Name
of registrant in its charter)
Nevada |
|
20-4754291 |
(State
or other jurisdiction of
incorporation
or organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
27936 Lost Canyon Road,
Suite 202,
Santa Clarita,
CA
91387
(Address
of principal executive offices) (Zip Code)
Issuer’s
telephone Number: (661)
251-0001
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
None |
|
None |
|
None |
Indicate
by check mark whether the registrant (1) has filed all reports
required by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of
“large accelerated filer,” “accelerated filer,” “smaller reporting
company” and “emerging growth company” in Rule 12b-2 of the
Exchange Act.
|
Large
accelerated filer ☐ |
Accelerated
filer ☐ |
|
Non-accelerated filer ☒ |
Smaller
reporting company
☒ |
|
|
Emerging
growth company
☐ |
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
The
number of shares of registrant’s common stock issued and
outstanding as of August 9, 2022 was
715,496,051.
NEWHYDROGEN,
INC.
INDEX
PART I – FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
NEWHYDROGEN,
INC.
CONDENSED BALANCE SHEET
The
accompanying notes are an integral part of these unaudited
condensed financial statements.
NEWHYDROGEN,
INC.
CONDENSED
STATEMENTS OF OPERATIONS
FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(Unaudited)
The
accompanying notes are an integral part of these unaudited
condensed financial statements.
NEWHYDROGEN,
INC.
CONDENSED STATEMENT OF SHAREHOLDERS’ DEFICIT
FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(Unaudited)
|
|
SIX MONTHS ENDED JUNE 30, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
|
|
|
Preferred
Stock |
|
|
|
|
|
Common
Stock |
|
|
Paid-in |
|
|
Accumulated |
|
|
|
|
|
|
Shares |
|
|
Amount |
|
|
Mezzanine |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Total |
|
Balance at December 31, 2021 |
|
|
- |
|
|
$ |
- |
|
|
$ |
3,485,313 |
|
|
|
715,496,051 |
|
|
$ |
71,549 |
|
|
$ |
164,000,447 |
|
|
$ |
(160,869,525 |
) |
|
$ |
3,202,471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock warrants for
cash |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,000 |
|
|
|
- |
|
|
|
1,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock and warrant compensation
cost |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
5,423,031 |
|
|
|
- |
|
|
|
5,423,031 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rounding |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(6,261,722 |
) |
|
|
(6,261,722 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 30, 2022
(unaudited) |
|
|
- |
|
|
$ |
- |
|
|
$ |
3,485,313 |
|
|
|
715,496,051 |
|
|
$ |
71,549 |
|
|
$ |
169,424,478 |
|
|
$ |
(167,131,247 |
) |
|
$ |
2,364,780 |
|
The
accompanying notes are an integral part of these unaudited
condensed financial statements.
NEWHYDROGEN,
INC.
CONDENSED STATEMENTS OF CASH FLOWS
FOR
THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(Unaudited)
The
accompanying notes are an integral part of these unaudited
condensed financial statements.
NEWHYDROGEN,
INC.
NOTES
TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED
FOR
THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021
1.
Basis of Presentation
The
accompanying unaudited condensed financial statements have been
prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial
information and with the instructions to Form 10-Q and Rule 10-01
of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of
management, all normal recurring adjustments considered necessary
for a fair presentation have been included. Operating results for
the six months ended June 30, 2022, are not necessarily indicative
of the results that may be expected for the year ending December
31, 2022. For further information refer to the financial statements
and footnotes thereto included in the Company’s Form 10-K for the
December 31, 2021.
Going Concern Substantial Doubt Alleviated
As of
the six months ended June 30, 2022, the Company had a net loss of
$6,261,722. As of June 30, 2022, its
shareholders equity was $2,364,780.
Management
believes the Company’s present cash flows will enable it to meet
its obligations for twenty-four months from the date of these
financial statements. Management will continue to assess it
operational needs and seek additional financing as needed to fund
its operations..
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
This
summary of significant accounting policies of the Company is
presented to assist in understanding the Company’s financial
statements. The financial statements and notes are representations
of the Company’s management, which is responsible for their
integrity and objectivity. These accounting policies conform to
accounting principles generally accepted in the United States of
America and have been consistently applied in the preparation of
the financial statements.
Revenue
Recognition
The
Company will recognize revenue when services are performed, and at
the time of shipment of products, provided that evidence of an
arrangement exists, title and risk of loss have passed to the
customer, fees are fixed or determinable, and collection of the
related receivable is reasonably assured. The Company adopted
Accounting Standards Codification (“ASC”) 606, whereby revenue will
be recognized as performance obligations are satisfied and
customers obtain control of goods or services. However, in the
event of a loss on a sale is foreseen, the Company will recognize
the loss as it is determined. To date, the Company has not had
significant revenues and is in the development stage.
Cash and Cash
Equivalent
The
Company considers all highly liquid investments with an original
maturity of three months or less to be cash equivalents.
Concentration
Risk
Cash
includes amounts deposited in financial institutions in excess of
insurable Federal Deposit Insurance Company (FDIC) limits. At times
throughout the year, the Company may maintain cash balances in
certain bank accounts in excess of FDIC limits. As of June 30,
2022, the cash balance in excess of the FDIC limits was $5,477,784. The Company has
not experienced any losses in such accounts and believes it is not
exposed to any significant credit risk in these
accounts.
Use of
Estimates
The
preparation of financial statements in conformity with generally
accepted accounting principles requires management to make
estimates and assumptions that affect the amounts reported in the
accompanying financial statements. Significant estimates made in
preparing these financial statements, include the estimate of
useful lives of property and equipment, the deferred tax valuation
allowance, derivative liabilities and the fair value of stock
options. Actual results could differ from those
estimates.
Property and
Equipment
Property
and equipment are stated at cost, and are depreciated using
straight line over its estimated useful lives:
SCHEDULE OF PROPERTY AND
EQUIPMENT
Computer
equipment |
|
|
5
Years |
|
Machinery
and equipment |
|
|
10
Years |
|
Depreciation
expense for the six months ended June 30, 2022 and 2021 was
$2,161 and $2,182, respectively.
NEWHYDROGEN,
INC.
NOTES
TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED
FOR
THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021
2. |
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (Continued) |
Intangible
Assets
The
Company has patent applications to protect the inventions and
processes behind its proprietary bio-based back-sheet, a protective
covering for the back of photovoltaic solar modules traditionally
made from petroleum-based film. Intangible assets that have finite
useful lives continue to be amortized over their useful
lives.
SCHEDULE OF INTANGIBLE ASSETS AMORTIZED OVER
THEIR USEFUL LIVES
|
|
Useful Lives |
|
6/30/ 2022 |
|
|
12/31/2021 |
|
Patents |
|
|
|
$ |
45,336 |
|
|
$ |
45,336 |
|
Less
accumulated amortization |
|
15 years |
|
|
(19,645 |
) |
|
|
(18,134 |
) |
Intangible assets |
|
|
|
$ |
25,691 |
|
|
$ |
27,202 |
|
Amortization
expense for the six months ended June 30, 2022 and the year ended
December 31, 2021 was $1,511 and $3,022, respectively.
Stock-Based
Compensation
The
Company measures the cost of employee services received in exchange
for an equity award based on the grant-date fair value of the
award. All grants under our stock-based compensation programs are
accounted for at fair value and that cost is recognized over the
period during which an employee, consultant, or director are
required to provide service in exchange for the award (the vesting
period). Compensation expense for options granted to employees and
non-employees is determined in accordance with the standard as the
fair value of the consideration received or the fair value of the
equity instruments issued, whichever is more reliably measured.
Compensation expense for awards granted is re-measured each
period.
On
March 24, 2015, the Company granted 2,450,000 stock options and on
September 2, 2015 granted 13,500,000 stock options to
its employees and directors for services. On March 24, 2022, the
2,450,000 options expired
leaving the September 2, 2015 options of 13,500,000
outstanding.
On
February 18, 2021, the Company granted 450,000,000 stock options to
its employees for services at an exercise price of $0.091. On September 29, 2021, the
Company amended the exercise price to $0.028 per share. The
options expire, and all rights to purchase the shares shall
terminate seven (7) years from the date of grant or termination of
employment. Half of the 400,000,000 options vested
immediately upon grant, and the remaining half of the option to
purchase 200,000,000 shares
of the Company’s common stock shall become exercisable in equal
amounts over a twenty-four (24) month period
during the term of the optionee’s employment, with the first
installment of 8,333,333 shares vesting on
March 18, 2021. The 50,000,000 options
are exercisable in equal amounts over a thirty-six (36) month period
during the term of the optionee’s employment, with the first
installment of 1,388,889 shares, vesting on
March 18, 2021. On April 12, 2022, the Company cancelled the
450,000,000 stock options dated
February 18, 2021, and concurrently granted 450,000,000 new options to
its’ employees for services.
On
March 1, 2022, the Company issued 5,000,000
common stock purchase warrants through a securities purchase
agreement for a purchase price of $1,000.
On
March 15, 2022, the Company granted 5,000,000 stock options to a
consultant for advisory services. The options vest at a rate of
138,889 options per month for a
thirty-six (36) month period during the term
of the optionee’s consultancy with the Company.
On
April 12, 2022, the Company granted 450,000,000 stock options to
its employees for services at an exercise price of $0.021. The options expire, and all
rights to purchase the shares shall terminate seven (7) years from the date of grant
or termination of employment. The vesting schedule of the 400,000,000 options are
exercisable in the amount of 316,666,662
immediately, and the remaining 83,333,338 shares
shall become exercisable in equal amounts over a ten (10) month period during the term
of the optionee’s employment until the Option is 100% vested. The 50,000,000 options are
exercisable in the amount of 19,444,446 immediately
and the remaining 30,555,554 shares
shall become exercisable in equal amounts over a twenty-two
(22) month period during the term
of the optionee’s employment until the Options is 100% vested.
Determining
the appropriate fair value of the stock-based compensation requires
the input of subjective assumptions, including the expected life of
the stock-based payment and stock price volatility. The Company
used Black Scholes to value its stock option awards which
incorporated the Company’s stock price, volatility, U.S. risk-free
rate, dividend rate, and estimated life. The stock options
terminate seven (7) years from the date of grant or upon
termination of employment. As of June 30, 2022, the
aggregate total of 468,500,000 stock options
were outstanding.
Research and
Development
Research
and development costs are expensed as incurred. Total research and
development costs were $451,092 and
$508,440 for the six
months ended June 30, 2022 and 2021, respectively.
NEWHYDROGEN,
INC.
NOTES
TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED
FOR
THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021
2. |
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (Continued) |
Net Earnings (Loss) per
Share Calculations
Net
earnings (Loss) per share dictates the calculation of basic
earnings (loss) per share and diluted earnings per share. Basic
earnings (loss) per share are computed by dividing by the weighted
average number of common shares outstanding during the year.
Diluted net earnings (loss) per share is computed similar to basic
earnings (loss) per share except that the denominator is increased
to include the effect of stock options and stock-based awards (Note
4), plus the assumed conversion of convertible debt (Note
5).
For
the six months ended June 30, 2022, the Company has not included
shares issuable from 468,500,000 stock options
and 228,958,334 warrants, because their impact
on the income per share is antidilutive.
The
Company has included shares issuable from convertible debt of
$107,000 and
440,950,000
stock options for the six months ended June 30, 2021, because their
impact on the income per share is dilutive.
SCHEDULE OF NET EARNINGS PER
SHARE
|
|
1 |
|
|
2 |
|
|
|
For
the Six Months Ended |
|
|
|
June 30, |
|
|
|
2022 |
|
|
2021 |
|
|
|
|
|
|
|
|
Income (Loss) to common shareholders (Numerator) |
|
$ |
(6,261,722 |
) |
|
$ |
47,114,733 |
|
|
|
|
|
|
|
|
|
|
Basic weighted average number of
common shares outstanding (Denominator) |
|
|
715,496,051 |
|
|
|
267,786,651 |
|
|
|
|
|
|
|
|
|
|
Diluted weighted average number
of common shares outstanding (Denominator) |
|
|
715,496,051 |
|
|
|
740,069,136 |
|
Fair Value of Financial
Instruments
Fair
Value of Financial Instruments requires disclosure of the fair
value information, whether recognized in the balance sheet, where
it is practicable to estimate that value. As of June 30, 2022, the
amounts reported for cash, inventory, prepaid expenses, accounts
payable, and accrued expenses, approximate the fair value because
of their short maturities.
Fair
value is defined as the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. ASC Topic 820
established a three-tier fair value hierarchy which prioritizes the
inputs used in measuring fair value. The hierarchy gives the
highest priority to unadjusted quoted prices in active markets for
identical assets or liabilities (level 1 measurements) and the
lowest priority to unobservable inputs (level 3 measurements).
These tiers include:
|
● |
Level
1, defined as observable inputs such as quoted prices for identical
instruments in active markets; |
|
|
|
|
● |
Level
2, defined as inputs other than quoted prices in active markets
that are either directly or indirectly observable such as quoted
prices for similar instruments in active markets or quoted prices
for identical or similar instruments in markets that are not
active; and |
|
|
|
|
● |
Level
3, defined as unobservable inputs in which little or no market data
exists, therefore requiring an entity to develop its own
assumptions, such as valuations derived from valuation techniques
in which one or more significant inputs or significant value
drivers are unobservable. |
We
measure certain financial instruments at fair value on a recurring
basis. As of June 30, 2022, there were no financial instruments to
report.
Recently Issued
Accounting Pronouncements
Management
does not believe that any recently issued, but not yet effective,
accounting standards if currently adopted would have a material
effect on the accompanying condensed financial
statements.
Reclassification
Certain
amounts in the 2021 financial statements have been reclassified to
conform to the presentation used in the 2022 financial statements.
There was no material impact on any of the Company’s previously
issued financial statements.
NEWHYDROGEN,
INC.
NOTES
TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED
FOR
THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021
3.
CAPITAL STOCK
Preferred Stock June 30, 2022
As of
June 30, 2022, the Company had a total of 34,853 shares of Series C
Preferred Stock outstanding with a fair value of $3,485,313,
and a stated face value of one hundred dollars ($100) per share which
are convertible into shares of fully paid and non-assessable shares
of common stock of the Company. The holder of the Series C
preferred stock are entitled to receive dividends pari passu with
the holders of common stock, except upon liquidation, dissolution
and winding up of the Corporation. The stock was presented as
mezzanine equity because it is redeemable at a fixed or
determinable amount upon an event that is outside of the issuer’s
control. The holder has the right, at any time, at its election, to
convert shares of Series C Preferred Stock into common stock at a
conversion price of $0.0014 and has no
voting rights.
Preferred Stock March 31, 2021
On
January 14, 2021, the Board of Directors
adopted a certificate of designation establishing the rights,
preferences, privileges and other terms of 1,000 Series B Preferred
Stock, par value $0.0001 per share, providing for supermajority
voting rights to holders of Series B Preferred Stock. The
shares of the Series B Preferred Stock were issued to David Lee,
Chief Executive Officer, Chairman of the Board, President and
acting Chief Financial Officer as consideration for his continued
employment with the Company.
On
March 26, 2021, the Company entered into a purchase agreement with
an investor for an exchange of convertible debt into equity. The
investor exchanged convertible notes in the amount of $2,462,060, plus
interest in the amount of $1,023,253 for an
aggregate total of $3,485,313
in exchange for 34,853 shares of the
Company’s Series C Preferred Stock. The extinguishment of the
convertible debt and derivative was recognized in the Company’s
financial statement as a gain on settlement of convertible notes
and derivative liability. A valuation was prepared based on a stock
price of $0.075, with a volatility of 206.03%, based on
an estimated term of 5
years.
SCHEDULE OF EXTINGUISHMENT OF
DEBT
Per Valuation |
|
|
|
Preferred shares issued |
|
|
34,853 |
|
Stated value of debt and
interest |
|
$ |
3,485,313 |
|
Calculated fair value of preferred shares |
|
$ |
85,555,201 |
|
Fair value of derivative liability
removed |
|
$ |
178,736,187 |
|
Gain |
|
$ |
(93,180,986 |
) |
The
Company recognized a gain on settlement of $93,180,986 for the extinguishment
of convertible debt, plus derivative liability for the six months
ended June 30, 2021.
Common Stock June 30, 2022
During
the six months ended June 30, 2022, the Company issued 5,000,000
common stock purchase warrants for cash in the amount of $1,000.
Common Stock June 30, 2021
During
the six months ended June 30, 2021, the Company issued an aggregate
of 52,000,000
shares of common stock and separate pre-funded warrants to purchase
up to 31,333,334
shares of common stock, plus warrants to purchase up to 83,333,334 at an
exercise price of $0.06 per share.
During
the six months ended June 30, 2021, the Company issued 65,000,000
shares of common stock and separate pre-funded warrants to purchase
up to 60,000,000
shares of common stock, plus warrants to purchase up to 125,000,000
at an exercise price of $0.04 per shares.
During
the six months ended June 30, 2021, the Company issued 21,964,188 shares of common
stock upon conversion of convertible promissory notes in the amount
of $184,124, plus accrued
interest of $20,851, and other fees of $1,000 at
prices ranging from $0.0014 - $0.0641.
During
the six months ended June 30, 2021, the Company issued 73,273,212 shares of common
stock upon conversion of convertible promissory notes in the amount
of $587,628, plus accrued
interest of $74,006, and other fees of
$500 at prices ranging from $0.00495 - $0.0172.
During
the six months ended June 30, 2021, the Company issued 1,000,000 shares of common
stock for services at fair value.
NEWHYDROGEN,
INC.
NOTES
TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED
FOR
THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021
3. |
CAPITAL
STOCK (Continued) |
Common Stock June 30, 2021 (Continued)
During
the six months ended June 30, 2021, the Company issued 28,000,000
shares of common stock upon conversion of 392
shares of preferred stock.
4.
STOCK OPTIONS AND WARRANTS
Stock Options
During
the six months ended June 30, 2022, the Company granted stock
options in the amount of 5,000,000. (See Note
2).
SCHEDULE OF STOCK OPTIONS
|
|
6/30/2022 |
|
|
|
Number of Options |
|
|
Weighted average exercise price |
|
Outstanding as of the
beginning of the periods |
|
|
465,950,000 |
|
|
$ |
0.0385 |
|
Granted |
|
|
455,000,000 |
|
|
$ |
0.0210 |
|
Exercised |
|
|
- |
|
|
|
- |
|
Expired/Cancelled |
|
|
(452,450,000 |
) |
|
$ |
0.0283 |
|
Outstanding as
of the end of the periods |
|
|
468,500,000 |
|
|
$ |
0.0279 |
|
Exercisable as
of the end of the periods |
|
|
376,265,187 |
|
|
$ |
0.0296 |
|
The
weighted average remaining contractual life of options outstanding
as of June 30, 2022 was as follows:
SCHEDULE OF WEIGHTED AVERAGE REMAINING
CONTRACTUAL LIFE OF OPTIONS OUTSTANDING
6/30/2022 |
|
|
|
|
Exercisable Price |
|
|
Stock Options Outstanding |
|
|
Stock
Options
Exercisable
|
|
|
Weighted Average Remaining Contractual Life (years) |
|
$ |
0.26 |
|
|
|
13,500,000 |
|
|
|
13,500,000 |
|
|
|
0.18 |
|
$ |
0.0223 |
|
|
|
5,000,000 |
|
|
|
488,584 |
|
|
|
2.71 |
|
$ |
0.021 |
|
|
|
450,000,000 |
|
|
|
362,276,603 |
|
|
|
6.79 |
|
|
|
|
|
|
468,500,000 |
|
|
|
376,265,187 |
|
|
|
|
|
The
stock-based compensation expense recognized in the statement of
operations during the six months ended June 30, 2022 related to
these options was $5,423,031.
As of
June 30, 2022, there was no intrinsic
value with regards to the outstanding options.
Warrants
During
the period ended June 30, 2022, the Company issued 5,000,000 common
stock purchase warrants through a securities purchase agreement for
a purchase price of $1,000.
SCHEDULE OF WARRANTS
ACTIVITY
|
|
6/30/2022 |
|
|
|
Number
of
Warrants
|
|
|
Weighted average exercise price |
|
Outstanding as of the
beginning of the periods |
|
|
223,958,334 |
|
|
$ |
0.0488 |
|
Issued |
|
|
- |
|
|
|
- |
|
Purchased |
|
|
5,000,000 |
|
|
$ |
0.0255 |
|
Expired |
|
|
- |
|
|
|
- |
|
Outstanding as
of the end of the periods |
|
|
228,958,334 |
|
|
$ |
0.0483 |
|
Exercisable as
of the end of the periods |
|
|
228,958,334 |
|
|
$ |
0.0483 |
|
NEWHYDROGEN,
INC.
NOTES
TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED
FOR
THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021
4. |
STOCK
OPTIONS AND WARRANTS (Continued) |
The
weighted average remaining contractual life of the warrants
outstanding as of June 30, 2022 was as follows:
SCHEDULE OF WARRANTS
OUTSTANDING
6/30/2022 |
|
Exercisable
Price |
|
|
Stock
Warrants Outstanding |
|
|
Stock
Warrants Exercisable |
|
|
Weighted
Average Remaining Contractual Life (years) |
|
$ |
0.0255 |
|
|
|
5,000,000 |
|
|
|
5,000,000 |
|
|
|
4.71 |
|
$ |
0.04 |
|
|
|
125,000,000 |
|
|
|
125,000,000 |
|
|
|
3.77 |
|
$ |
0.05 |
|
|
|
9,375,000 |
|
|
|
9,375,000 |
|
|
|
3.76 |
|
$ |
0.06 |
|
|
|
83,333,334 |
|
|
|
83,333,334 |
|
|
|
4.08 |
|
$ |
0.075 |
|
|
|
6,250,000 |
|
|
|
6,250,000 |
|
|
|
4.08 |
|
|
|
|
|
|
228,958,334 |
|
|
|
228,958,334 |
|
|
|
|
|
During
the period, the Company recognized warrant compensation at fair
value in the amount $115,102.
5.
COMMITMENTS AND CONTINGENCIES
The
Company rents office space on a yearly basis with a monthly rent
payment in the amount of $550.
In the normal course of business, the Company may be involved in
legal proceedings, claims and assessments arising. Such matters are
subject to many uncertainties, and outcomes are not predictable
with assurance. In the opinion of management, the ultimate
disposition of these matters will not have a material adverse
effect on the Company’s financial position or results of
operations.
On March 15, 2022, the Company entered into an advisor agreement
for services regarding various aspects of the Company’s business,
including but not limited to technology, business development, and
product development. The Company granted 5,000,000 common stock
options, vesting at a rate of 138,889 options per month for
thirty-six (36) months of consecutive service to the Company, as
well as cash compensation of $5,000 per month for the services
provided.
As of
June 30, 2022, there were no legal proceedings against the
Company.
6.
SUBSEQUENT EVENT
Management
has evaluated subsequent events according to the requirements of
ASC TOPIC 855 and has reported no subsequent events.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
Special
Note on Forward-Looking Statements.
Certain
statements in “Management’s Discussion and Analysis and Results of
Operations” below, and elsewhere in this quarterly report, are not
related to historical results, and are forward-looking statements.
Forward-looking statements present our expectations or forecasts of
future events. You can identify these statements by the fact that
they do not relate strictly to historical or current facts. These
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from any
future results, levels of activity, performance or achievements
expressed or implied by such forward-looking statements.
Forward-looking statements frequently are accompanied by such words
such as “may,” “will,” “should,” “could,” “expects,” “plans,”
“intends,” “anticipates,” “believes,” “estimates,” “predicts,”
“potential” or “continue,” or the negative of such terms or other
words and terms of similar meaning. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance, achievements, or timeliness of such results. Moreover,
neither we nor any other person assumes responsibility for the
accuracy and completeness of such forward-looking statements. We
are under no duty to update any of the forward-looking statements
after the date of this quarterly report. Subsequent written and
oral forward looking statements attributable to us or to persons
acting on our behalf are expressly qualified in their entirety by
the cautionary statements and risk factors set forth in our annual
report on Form 10-K filed with the SEC on June 30, 2022, and in
other reports filed by us with the SEC.
You
should read the following description of our financial condition
and results of operations in conjunction with the financial
statements and accompanying notes included in this
report.
Overview
We
are a developer of Green Hydrogen technologies. Our current focus
is on developing an electrolyzer technology to lower the cost of
Green Hydrogen production. Green Hydrogen is the term used to refer
to Hydrogen fuel that is created using renewable energy instead of
fossil fuels.
Hydrogen
is the cleanest and most abundant fuel in the universe. It is
zero-emission and only produces water vapor when used. However,
hydrogen does not exist in its pure form on Earth so it must be
extracted. For centuries, scientists have known how to utilize
electricity to split water into hydrogen and oxygen using a device
called an electrolyzer. Electrolyzers installed behind a solar farm
or wind farm can use renewable electricity to split water, thereby
producing Green Hydrogen. However, modern electrolyzers still cost
too much. The chemical catalysts that enable the water-splitting
reactions are currently made from platinum and iridium – both are
very expensive precious metals. These catalysts account for nearly
50% of the cost of the electrolyzer.
We
are developing technologies to significantly reduce or replace rare
earth materials with inexpensive earth abundant materials in
electrolyzers to help usher in a Green Hydrogen economy.
As of
April 30, 2021, we changed our name from BioSolar, Inc. to
NewHydrogen, Inc.
Recent
Transactions
None.
Application
of Critical Accounting Policies
Our
discussion and analysis of our financial condition and results of
operations are based upon our unaudited financial statements, which
have been prepared in accordance with accounting principles
generally accepted in the United States of America. The preparation
of these financial statements requires us to make estimates and
judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosures of contingent assets
and liabilities. On an ongoing basis, we evaluate our estimates,
including those related to impairment of property, plant and
equipment, intangible assets, deferred tax assets and fair value
computation using a Binomial lattice valuation model. We base our
estimates on historical experience and on various other
assumptions, such as the trading value of our common stock and
estimated future undiscounted cash flows, that we believe to be
reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying value of assets and
liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates under different
assumptions or conditions; however, we believe that our estimates,
including those for the above-described items, are
reasonable.
Use
of Estimates
The
preparation of financial statements in conformity with generally
accepted accounting principles requires management to make
estimates and assumptions that affect the amounts reported in the
accompanying financial statements. Significant estimates made in
preparing these financial statements, include the estimate of
useful lives of property and equipment, the deferred tax valuation
allowance, derivative liabilities and the fair value of stock
options. Actual results could differ from those
estimates.
Fair
Value of Financial Instruments
Our
cash, cash equivalents, investments, inventory, prepaid expenses,
and accounts payable are stated at cost which approximates fair
value due to the short-term nature of these instruments.
Recently
Issued Accounting Pronouncements
Management
reviewed currently issued pronouncements during the three months
ended June 30, 2022, and does not believe that any other recently
issued, but not yet effective, accounting standards if currently
adopted would have a material effect on the accompanying condensed
unaudited financial statements.
Results
of Operations – Three Months Ended June 30, 2022 Compared to the
Three Months Ended June 30, 2021.
OPERATING
EXPENSES
General and Administrative Expenses
General
and administrative (“G&A”) expenses increased by $407,667 to
$3,229,645 for the three months ended June 30, 2022, compared to
$3,637,312 for the prior period ended June 30, 2021. The primary
increase in G&A expenses was the result of an decrease in fair
value of non-cash stock compensation of $407,702, an increase in
professional fees in the amount of $4,026, with an overall decrease
in G&A expenses of $3,991.
Research and Development
Research
and Development (“R&D”) expenses decreased by $21,230 to
$230,546 for the three months ended June 30, 2022, compared to
$251,776 for the prior period ended June 30, 2021. This overall
decrease in R&D expenses was the result of a decrease in
outside research fees.
Depreciation
Depreciation
expense for the three months ended June 30, 2022 and 2021 was
$1,070 and $1,091, respectively.
Other Income/(Expenses)
Other
income and (expenses) decreased by $234,634 to $601 for the three
months ended June 30, 2022, compared to $235,235 for the prior
period ended June 30, 2021. The decrease in other income and
(expenses) was the result of a decrease in gain of non-cash
accounts associated with the change in fair value of the derivative
instruments of $250,293, a decrease in interest expense of $15,977,
which includes non-cash expense of amortization of debt discount in
the amount of $13,338, with a decrease in interest income of $318.
The decrease in other income and (expenses) was primarily due to
the net change in the fair value of the derivative
instruments.
Net Income (Loss)
Our
net loss for the three months ended June 30, 2022 was $(3,460,660),
compared to $(3,654,944) for the prior period ended June 30, 2021.
The increase in net loss was due to an increase in non-cash other
income associated with the net change in derivative instruments
estimated in the current period. These estimates were based on
multiple inputs, including the market price of our stock, interest
rates, our stock price volatility, variable conversion prices based
on market prices as defined in the respective agreements and
probabilities of certain outcomes based on management projections.
These inputs were subject to significant changes from period to
period and to management’s judgment; therefore, the estimated fair
value of the derivative liabilities fluctuate from period to
period, and the fluctuation may be material. The Company has not
generated any revenues.
Results
of Operations – Six Months Ended June 30, 2022 Compared to the Six
Months Ended June 30, 2021.
OPERATING
EXPENSES
General and Administrative Expenses
G&A
expenses decreased by $12,629,126 to $5,809,704 for the six months
ended June 30, 2022, compared to $18,438,830 for the prior period
ended June 30, 2021. The primary decrease in G&A expenses was
the result of a decrease in fair value of non-cash stock
compensation of $12,390,803, a decrease in professional fees in the
amount of $263,558, with an overall increase in G&A expenses of
$25,235.
Research and Development
R&D
expenses decreased by $57,348 to $451,092 for the six months ended
June 30, 2022, compared to $508,440 for the prior period ended June
30, 2021. This overall decrease in R&D expenses was the result
of a decrease in outside research fees.
Depreciation
Depreciation
expense for the six months ended June 30, 2022 and 2021 was $2,161
and $2,182, respectively.
Other Income/(Expenses)
Other
income and (expenses) decreased by $66,062,950 to $1,235 for the
six months ended June 30, 2022, compared to $66,064,185 for the
prior period ended June 30, 2021. The decrease in other income and
(expenses) was the result of a decrease in gain of non-cash
accounts associated with the change in fair value of the derivative
instruments of $66,626,814, a decrease in interest expense of
$563,914, which includes non-cash expense of amortization of debt
discount in the amount of $449,100, with a decrease in interest
income of $50. The decrease in other income and (expenses) was
primarily due to the net change in the fair value of the derivative
instruments.
Net Income (Loss)
Our
net loss for the six months ended June 30, 2022 was $(6,261,722),
compared to net income of $47,114,733 for the prior period ended
June 30, 2021. The decrease in net loss was due to a decrease in
non-cash other expenses associated with the net change in
derivative instruments estimated in the current period. These
estimates were based on multiple inputs, including the market price
of our stock, interest rates, our stock price volatility, variable
conversion prices based on market prices as defined in the
respective agreements and probabilities of certain outcomes based
on management projections. These inputs were subject to significant
changes from period to period and to management’s judgment;
therefore, the estimated fair value of the derivative liabilities
fluctuate from period to period, and the fluctuation may be
material. The Company has not generated any revenues.
LIQUIDITY
AND CAPITAL RESOURCES
Liquidity
is the ability of a company to generate funds to support its
current and future operations, satisfy its obligations, and
otherwise operate on an ongoing basis. Significant factors in the
management of liquidity are funds generated by operations, levels
of accounts receivable and accounts payable and capital
expenditures.
The
unaudited condensed financial statements have been prepared on a
going concern basis of accounting, which contemplates continuity of
operations, realization of assets and liabilities and commitments
in the normal course of business. The accompanying unaudited
condensed financial statements do not reflect any adjustments that
might result if we are unable to continue as a going concern.
During the six months ended June 30, 2022, we did not generate any
revenues, and recognized a net loss of $(6,261,722), due to a
change in non-cash stock compensation, and cash of $866,147 used in
operations. As of June 30, 2022, we had working capital of
$6,035,970 and a shareholders’ equity of $2,364,780.
Management
believes that we will be able to continue to raise funds through
the sale of our securities to existing and new investors.
Management believes that funding from existing and prospective new
investors and future revenue will provide the additional cash
needed to meet our obligations as they become due and will allow
the development of our core business operations. No assurance can
be given that any future financing will be available or, if
available, that it will be on terms that are satisfactory to the
Company. Even if the Company is able to obtain additional
financing, it may contain undue restrictions on our operations, in
the case of debt financing or cause substantial dilution for our
stockholders, in case of equity financing.
As of
June 30, 2022, we had working capital of $5,820,423 compared to
$6,655,953 for the year ended December 31, 2021. This decrease in
working capital was due primarily to a decrease in cash.
During
the six months ended June 30, 2022, we used $866,147 of cash for
operating activities, as compared to $1,264,374 for the prior six
months period ended June 30, 2021. The decrease in the use of cash
for operating activities for the current period was a result of a
decrease in professional fees and research and development
cost.
Net
cash provided from equity financing activities was $1,000 for the
six months ended June 30, 2022, as compared to $8,770,700 for the
prior period ended June 30, 2021. The decrease was due to less
equity financing during the current period. Our capital needs have
primarily been met from the proceeds of the sale of our securities,
as we currently have not generated any revenues.
Our
independent auditors, in their report on our audited financial
statements for the year ended December 31, 2021, expressed
substantial doubt about our ability to continue as a going concern.
Our financial statements as of June 30, 2022 have been prepared
under the assumption that we will continue as a going concern. Our
ability to continue as a going concern ultimately is dependent upon
our ability to generate revenue, which is dependent upon our
ability to obtain additional equity or debt financing, attain
further operating efficiencies and, ultimately, to achieve
profitable operations. Our financial statements do not include any
adjustments that might result from the outcome of this
uncertainty.
PLAN
OF OPERATION AND FINANCING NEEDS
We
are engaged in the development of innovative technologies to
significantly reduce or replace catalysts made from rare earth
materials with catalysts made from inexpensive earth abundant
materials in electrolyzers to lower the cost of producing Green
Hydrogen.
Our
plan of operation within the next three months is to utilize our
cash balances to work on developing catalyst technologies for
producing Green Hydrogen. We believe that our current cash and
investment balances will be sufficient to support development
activity and general and administrative expenses for the next
twenty-four months. Management estimates that it will require
additional cash resources during 2024, based upon its current
operating plan and condition. We do expect increased expenses
during the third quarter of 2022. There is no assurance that
capital in any form would be available to us, and if available, on
terms and conditions that are acceptable. If we are unable to
obtain sufficient funds during the next twenty-four months, we may
be forced to reduce the size of our organization, which could have
a material adverse impact on, or cause us to curtail and/or cease
the development of our products
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK
As a
smaller reporting company, as that term is defined in Item 10(f)(1)
of Regulation S-K, we are not required to provide information
required by this Item.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation
of Disclosure Controls and Procedures
As of
the end of the period covered by this report, we conducted an
evaluation, under the supervision and with the participation of our
chief executive officer and acting chief financial officer of our
disclosure controls and procedures (as defined in Rule 13a-15(e)
and Rule 15d-15(e) of the Exchange Act). Based upon this
evaluation, our chief executive officer and chief financial officer
concluded as of June 30, 2022, that our disclosure controls and
procedures are effective to ensure that information required to be
disclosed by us in the reports that we file or submit under the
Exchange Act is: (i) recorded, processed, summarized and reported,
within the time periods specified in the Commission’s rules and
forms, and (ii) accumulated and communicated to our management,
including our chief executive officer and acting chief financial
officer, or person performing similar functions, as appropriate to
allow timely decisions regarding required disclosure.
Changes
in Internal Control over Financial Reporting
There
was no change to our internal control over financial reporting that
occurred during our first fiscal quarter that has materially
affected, or is reasonably likely to materially affect, our
internal control over financial reporting.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
As of
the date of this report, we are not a party to any pending legal
proceeding, nor is our property the subject of a pending legal
proceeding, that is not in the ordinary course of business or
otherwise material to the financial condition of our business. None
of our directors, officers or affiliates is involved in a
proceeding adverse to our business or has a material interest
adverse to our business.
ITEM 1A. RISK FACTORS
There
are no material changes from the risk factors previously disclosed
in the Registrant’s annual report on Form 10-K filed on March 31,
2022.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS
None
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not
applicable.
ITEM 5. OTHER INFORMATION
None.
ITEM 6. EXHIBITS
SIGNATURES
In
accordance with Section 13 or 15(d) of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Los Angeles,
State of California, on August 10, 2022.
|
NEWHYDROGEN,
INC. |
|
|
|
By: |
/s/
David Lee |
|
|
Chief
Executive Officer
(Principal
Executive Officer) and
Acting
Chief Financial Officer
(Principal
Financial Officer and
Principal
Accounting Officer)
|
NewHydrogen (PK) (USOTC:NEWH)
Historical Stock Chart
From Jan 2023 to Feb 2023
NewHydrogen (PK) (USOTC:NEWH)
Historical Stock Chart
From Feb 2022 to Feb 2023